pharma

Datavant, a fledgling spinoff from Roivant Sciences, is trying to break down information silos that often lead to poorly designed clinical trials.

Version 5.0 of the software features tools for normalizing concepts such as gene mutations and additional query features for mining text documents.

The launch follows a beta that kicked off earlier this year to put the software through its paces with data curators and other scientists.

The resource will offer easy access to an inventory of vendors with patient-derived xenograph models as well as associated molecular data for oncology drug discovery projects.

The custom software development company will soon test a tool called 5AM Sunrise for managing and aggregating clinical and molecular data.

The company is working on a bespoke pharmacovigilance product that will leverage its biomedical content, and has added an NGS module to Pathway Studio. 

The company will use some of the funds to set up a new research laboratory within the US to better support collaborations with pharma and biotech.

Lonza now offers kits and services featuring Roche's MycoTool detection kits for final release testing of pharmaceutical products, upon validation. In the meantime, Lonza continues to develop its own pharma QC products, including mycoplasma detection assays, on BD's automated testing platform.

BD Diagnostics and Switzerland's Lonza have inked an agreement to develop and commercialize Lonza's microCompass molecular assays on the BD Max system for pharmaceutical quality-control testing.

HCP and BioMed Realty, two of the nation's largest publicly-traded owners of life sciences space, offered largely upbeat updates on their businesses this week following the release of their quarterly financial results.

Pages

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.